Premature aging conditions are where NAD+ research has produced its most concrete human results so far. NAD+ is the coenzyme at the center of cellular energy metabolism, and hundreds of papers describe how it participates in DNA repair, genome stability, redox balance, mitochondrial health, and telomere maintenance (Bohr, 2026). Most of that work was done in animals or in cells. The harder question is what it means for people, and the sharpest way to ask it is to look at patients whose bodies age far faster than their birthdays suggest.
Part 01: Premature Aging Research Begins With NAD+
The mechanisms themselves are not in dispute. NAD+ is a substrate for the sirtuin and PARP enzyme families, which handle stress response, inflammation control, and DNA repair, and it is required for the electron transport chain that produces ATP. Animal models have repeatedly shown that raising NAD+ availability changes metabolic and tissue function. Translating that into general anti-aging advice has been difficult, because healthy adults start from very different baselines, the endpoints move slowly, and any effect is hard to separate from lifestyle.
Patients with premature aging disorders make the measurement easier. Their decline is accelerated, measurable, and documented, and symptoms appear early enough for a trial to follow them within a realistic time frame. When something moves in this group, the signal is easier to read than it would be in a healthy population of the same size.
One caveat belongs at the start. Results from rare premature aging disorders do not transfer to healthy adults shopping for a longevity supplement. The populations, the biology, and the endpoints are all different, and the trials described below were designed to test safety and disease-related measures rather than general anti-aging effects.
Part 02: Why Blood NAD+ Does Not Predict Premature Aging
The most repeated claim in longevity writing is that NAD+ falls with age. The measured data are more uneven than that sentence suggests. Yang and colleagues measured whole blood NAD+ in 1,518 adults aged 18 and older. Men averaged 34.5 micromoles per liter and women 31.3. A downward trend appeared before age 50, reached significance in the 40 to 49 group, and then disappeared. In men, the 60 and older group was significantly lower than the under 29 group. In women, no significant difference appeared between any of the five age groups (Yang et al., 2022).
The same study reported wide variation between people of the same age, with some participants well above the average for their bracket. Sample size, measurement method, and differences between tissues are all plausible explanations for the uneven picture. Whatever the cause, the practical point holds: age is a poor predictor of who is short on NAD+, and someone whose level sits near the average for their age has little room for a large response to supplementation.
That variability is part of why research into premature aging disorders gets quoted so often. In a patient with a known defect in DNA repair, the depletion has a documented mechanism behind it rather than a statistical trend, which is a far stronger starting point for a clinical trial.
Part 03: The Rare Diseases That Turn Premature Aging Into a Diagnosis
If an anti-aging drug existed, the people who needed it most would not be healthy adults in their sixties. They would be the patients whose decline starts in childhood or adolescence. Four conditions make up the best-known group.
The Four Best-Known Premature Aging Disorders
- Werner syndrome (WS). Caused by WRN gene mutations that impair DNA double-strand break repair. Signs appear in the teens or later and include gray hair, muscle wasting, and diabetes, with many patients unable to live past 60. NAD+ is low and mitophagy is defective.
- Cockayne syndrome (CS). Caused by CSA or CSB mutations affecting transcription-coupled nucleotide excision repair. Growth failure, neurodegeneration, light sensitivity, and premature aging appear early in life.
- Ataxia telangiectasia (AT). Caused by ATM mutations that disrupt regulation of double-strand break repair. Cerebellar ataxia, neurodegeneration, immunodeficiency, and features of premature aging develop across childhood.
- Xeroderma pigmentosum (XP). Caused by XPA and related mutations in nucleotide excision repair. Skin cancer risk is extremely high, and severe neurodegeneration occurs in some patients.
All four share one underlying problem: a DNA repair system that does not work. Damage that healthy cells would correct accumulates instead, which produces progressive cell dysfunction and cell death, and the loss of those cells shows up as failing organ function. Onset ranges from infancy to after puberty. Risks of cardiovascular disease, cataracts, neurodegeneration, infection, and cancer run well above those of the general population. For these patients, even sunlight carries a cost: ultraviolet radiation damages skin-cell DNA that their repair machinery cannot fix.
The result is a life that is both compressed and sped up. For patients with premature aging disorders, the burden of aging arrives decades before it should.
Part 04: How Premature Aging Depletes Cellular NAD+
The mechanism connecting these conditions to NAD+ is specific rather than general. Persistent DNA damage keeps PARP1 active, and PARP1 is one of the main consumers of NAD+ in the cell. Continuous activation drains the pool and leaves less substrate for SIRT1, an enzyme that depends on NAD+ availability to carry out its role in energy regulation and mitochondrial quality control. With SIRT1 activity reduced, energy production and mitophagy suffer, and the cell moves toward severe dysfunction or death (Bohr, 2026).
Why Premature Aging Cells Run Out of NAD+
That sequence is why NAD+ supplementation is a rational hypothesis in this setting rather than a blanket longevity claim. If NAD+ depletion is one step in the pathology, supplying precursors could plausibly protect cell function and survival in patients whose defect cannot be corrected at the gene level. The hypothesis was first tested in model organisms, where NAD+ augmentation improved mitochondrial function and reduced senescence markers in cells derived from these patients (Bohr, 2026).
(Comparison of a Werner syndrome patient at age 15 (left) and age 48 (right). Image Source: https://www.eurekalert.org/multimedia/1076498)
Part 05: Nicotinamide Riboside Trials in Premature Aging Conditions
Nicotinamide riboside, or NR, is an oral NAD+ precursor that reliably raises blood NAD+ in humans. Three trials have now tested it in two of these premature aging conditions.
Nicotinamide Riboside in Werner Syndrome
The first controlled test in Werner syndrome was a 52 week randomized, double-blind, crossover, placebo-controlled trial in 9 patients with a mean age of 47 (Shoji et al., 2025). Participants took 1,000 mg of NR daily or placebo for 26 weeks, then crossed to the other arm for 26 weeks. Plasma NAD+ rose by about 140 percent on NR. The trial also reported reduced arterial stiffness, lipid changes associated with cardiovascular protection, support for wound healing, and improved kidney function. Shoji’s group also reported 7 cases of mild adverse events in the NR group and 12 cases in the placebo group, alongside observed mild elevations in liver enzymes. The authors concluded that these events are manageable, and align with the hepatic sensitivity commonly seen in Werner syndrome itself. The authors described the outcome as support for further research rather than established benefit, and 9 participants is a small group from which to generalize.
Nicotinamide Riboside in Ataxia Telangiectasia
An earlier open-label study treated 24 patients with ataxia telangiectasia for four months at 25 mg per kilogram of body weight per day, then followed them for two months without treatment (Veenhuis et al., 2021). Ataxia scores improved during treatment: mean totals fell to 2.4 on the Scale for the Assessment and Rating of Ataxia and to 10.1 on the International Cooperative Ataxia Rating Scale. Immunodeficient patients showed sustained rises in serum IgG. No adverse events were reported. When treatment stopped, the improvement reversed, and the study had no placebo arm.
A longer single-arm study treated 10 patients with ataxia telangiectasia at 500 mg daily of NR for two years (Presterud et al., 2024). Blood NAD+ rose quickly and stayed above baseline. At the 18 month assessment, all but one participant improved on a panel of neuromotor tests, driven mainly by coordination and eye movement subscores, and comparison with historical data suggested slower progression than expected. This remains the longest conducted NR trial, showing that NR is well tolerated by most participants; however, the absence of a control group limits the conclusions it can draw.
Read together, the three trials point in one direction without settling the question. The populations were small, two of the three were open label, and all enrolled people with a diagnosed genetic disease rather than healthy adults. They support continued research in premature aging disorders. They do not support claims about anti-aging effects in the general population.
Part 06: Conclusion: Premature Aging Is Not the Only Story NAD+ Tells
The evidence now sits in three layers. The biology is clear, in that NAD+ depletion is a documented consequence of defective DNA repair: sustained PARP1 activity drains the same pool that SIRT1 depends on (Bohr, 2026). Population data are messier, showing a decline that is neither uniform nor steep and that differs by sex (Yang et al., 2022). Human trials are still early, small, and restricted to rare disease (Shoji et al., 2025; Veenhuis et al., 2021; Presterud et al., 2024).
It is also worth being plain about what supplementation cannot do. It does not correct a mutated WRN, ATM, or XPA gene, and it does not replace gene therapy, supportive care, or genetic counseling. For a family facing one of these diagnoses, a supplement is not the intervention that changes the underlying condition, and for premature aging disorders the search for that intervention continues.
A scope note is warranted here. The trials above tested nicotinamide riboside, not the NADH formats sold by any particular brand. Celfull follows this research because NAD+ metabolism is the field the company works in, and nothing described above should be read as a product claim.
None of this replaces a clinician. In rare genetic disease, decisions about supplementation belong with the treating team, and in healthy adults the case for routine use is not established.
What the early trials do change is the framing. Slow progress in a disease that normally moves fast is not a cure, and it was never going to be one. It is the first sign that the question was aimed at the right place.
References
Bohr V A. Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage[J]. Aging Cell, 2026, 25(1): e70319. https://pubmed.ncbi.nlm.nih.gov/41436848/
Shoji M, Kato H, Koshizaka M, et al. Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial[J]. Aging Cell, 2025, 24(8): e70093. https://pubmed.ncbi.nlm.nih.gov/40459998/
Veenhuis S J G, van Os N J H, Janssen A J W M, et al. Nicotinamide riboside improves ataxia scores and immunoglobulin levels in ataxia telangiectasia[J]. Movement Disorders, 2021, 36(12): 2951-2957. https://pubmed.ncbi.nlm.nih.gov/34515380/
Presterud R, Deng W H, Wennerström A B, et al. Long-term nicotinamide riboside use improves coordination and eye movements in ataxia telangiectasia[J]. Movement Disorders, 2024, 39(2): 360-369. https://pubmed.ncbi.nlm.nih.gov/37899683/
Yang F, Deng X, Yu Y, et al. Association of Human Whole Blood NAD+ Contents With Aging[J]. Frontiers in Endocrinology, 2022, 13: 829658. https://pubmed.ncbi.nlm.nih.gov/35388296/
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The information and ingredients described in this article are for research purposes only. They are not intended to diagnose, treat, cure, or prevent any disease.
